Yura Jang,Sungtaek Oh,Anna J. Hall,Zhen Zhang,Thomas F. Tropea,Alice Chen-Plotkin,Liana S. Rosenthal,Ted M. Dawson,Chan Hyun Na,Alexander Y. Pantelyat

Abstract:Progressive supranuclear palsy (PSP) is a neurodegenerative disorder often misdiagnosed as Parkinson's Disease (PD) due to shared symptoms. PSP is characterized by the accumulation of tau protein in specific brain regions, leading to loss of balance, gaze impairment, and dementia. Diagnosing PSP is challenging, and there is a significant demand for reliable biomarkers. Existing biomarkers, including tau protein and neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF), show inconsistencies in distinguishing PSP from other neurodegenerative disorders. Therefore, the development of new biomarkers for PSP is imperative.

Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid